Kameel D. Farag insider trades

Open-market stock purchases and sales by Kameel D. Farag, Interim CFO at Akari Therapeutics plc, from SEC Form 4 filings since Oct 22, 2025.

Recent trades

DateStockTradeValue
Jun 24, 2026AKTX Akari Therapeutics plcBought (not open market)$12.5K
Jun 24, 2026AKTX Akari Therapeutics plcBought (not open market)$13K
Jun 24, 2026AKTX Akari Therapeutics plcBought (not open market)$13K
Jun 24, 2026AKTX Akari Therapeutics plcBought (not open market)$13K
Jun 24, 2026AKTX Akari Therapeutics plcBought (not open market)$13K
Jun 24, 2026AKTX Akari Therapeutics plcBought (not open market)$27.5K
Jun 24, 2026AKTX Akari Therapeutics plcBought (not open market)$13K
Jan 5, 2026BIVI Biovie IncBought (not open market)—
Dec 16, 2025AKTX Akari Therapeutics plcBought$10K
Nov 1, 2025AKTX Akari Therapeutics plcBought (not open market)$24K
Nov 1, 2025AKTX Akari Therapeutics plcBought (not open market)$20K
Oct 22, 2025AKTX Akari Therapeutics plcBought (not open market)$4.6K

Companies traded

  • AKTX Akari Therapeutics plc: 1 buy, last Jun 24, 2026
  • BIVI Biovie Inc: other filings, last Jan 5, 2026

Get free alerts when Kameel D. Farag files a new trade →